1. Home
  2. STKS vs BOLD Comparison

STKS vs BOLD Comparison

Compare STKS & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The ONE Group Hospitality Inc.

STKS

The ONE Group Hospitality Inc.

N/A

Current Price

$1.50

Market Cap

52.7M

ML Signal

N/A

Logo Boundless Bio Inc.

BOLD

Boundless Bio Inc.

SELL

Current Price

$2.43

Market Cap

60.8M

Sector

N/A

ML Signal

SELL

Company Overview

Basic Information
Metric
STKS
BOLD
Founded
2004
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
52.7M
60.8M
IPO Year
2011
2024

Fundamental Metrics

Financial Performance
Metric
STKS
BOLD
Price
$1.50
$2.43
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
★ $4.45
N/A
AVG Volume (30 Days)
16.5K
★ 148.7K
Earning Date
11-05-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 32.47
EPS
★ N/A
N/A
Revenue
★ $805,722,000.00
N/A
Revenue This Year
$0.77
N/A
Revenue Next Year
$7.93
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 19.66
N/A
52 Week Low
$1.50
$0.96
52 Week High
$2.90
$3.16

Technical Indicators

Market Signals
Indicator
STKS
BOLD
Relative Strength Index (RSI) 39.03 32.14
Support Level N/A $2.40
Resistance Level $1.71 $2.90
Average True Range (ATR) 0.07 0.15
MACD -0.00 -0.02
Stochastic Oscillator 17.65 5.71

Price Performance

Historical Comparison
STKS
BOLD

About STKS The ONE Group Hospitality Inc.

The One Group Hospitality Inc is a restaurant company that develops, owns and operates, manages and licenses upscale and polished casual, high-energy restaurants and lounges and provides turn-key food and beverage (F&B) services for hospitality venues, including hotels, casinos, and other high-end locations internationally. The company operates through three segments: STK, Benihana and Grill Concepts. The company generates the vast majority of its revenue from the domestic market.

About BOLD Boundless Bio Inc.

Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

Share on Social Networks: